First Wave BioPharma, Inc. (formerly AzurRx BioPharma) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

First Wave is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. 

 Conference Call:  First Wave BioPharma, Formerly AzurRx BioPharma, Acquires First Wave Bio  Sept. 13, 2021


logo ICO


777 Yamato Road Suite 502
Boca Raton, FL 33431
(561) 589-7020